Title: A Study on Prevention of Bleeding Complications Using Lusutrombopag for Safe RFA in
Patients with Hepatocellular Carcinoma with Low Platelet Counts: Prospective Observational
Study.
Version: 2 Date: 08 Mar 2023
Reviewer's report:
In this study, the researchers examined the safety and efficacy of lusutrombopag to avoid
bleeding complications after radiofrequency ablation (RFA) in patients with hepatocellular
carcinoma and a low platelet count. The results were satisfactory. The Reviewer has the
following comments.
1. The study design should be described in the Method section: a prospective or retrospective
study, whether informed consent was obtained or not, and so on.
2. The details should be described regarding the RFA procedure, such as the type of the RF
needle (single or expandable) and the removal of the RFA needles with or without needle tract
ablation.
3. The same term for hepatocellular carcinoma but not liver cancer should be used in the text.
4. Were there other side effects or complications associated with the use of lusutrombopag? The
authors should describe all of them.
5. In the Discussion section, the researchers should refer to the small number of the enrolled
patients as an evaluation of a certain drug in this study.
Title: A Study on Prevention of Bleeding Complications Using Lusutrombopag for Safe RFA in
Patients with Hepatocellular Carcinoma with Low Platelet Counts: Prospective Observational
Study.
Version: 2 Date: 08 Mar 2023
Reviewer's report:
In this study, the researchers examined the safety and efficacy of lusutrombopag to avoid
bleeding complications after radiofrequency ablation (RFA) in patients with hepatocellular
carcinoma and a low platelet count. The results were satisfactory. The Reviewer has the
following comments.
1. The study design should be described in the Method section: a prospective or retrospective
study, whether informed consent was obtained or not, and so on.
2. The details should be described regarding the RFA procedure, such as the type of the RF
needle (single or expandable) and the removal of the RFA needles with or without needle tract
ablation.
3. The same term for hepatocellular carcinoma but not liver cancer should be used in the text.
4. Were there other side effects or complications associated with the use of lusutrombopag? The
authors should describe all of them.
5. In the Discussion section, the researchers should refer to the small number of the enrolled
patients as an evaluation of a certain drug in this study.
Please review this paper.
user
Title: A Study on Prevention of Bleeding Complications Using Lusutrombopag for Safe RFA in
Patients with Hepatocellular Carcinoma with Low Platelet Counts: Prospective Observational
Study.
Version: 2 Date: 08 Mar 2023
Reviewer's report:
In this study, the researchers examined the safety and efficacy of lusutrombopag to avoid
bleeding complications after radiofrequency ablation (RFA) in patients with hepatocellular
carcinoma and a low platelet count. The results were satisfactory. The Reviewer has the
following comments.
1. The study design should be described in the Method section: a prospective or retrospective
study, whether informed consent was obtained or not, and so on.
2. The details should be described regarding the RFA procedure, such as the type of the RF
needle (single or expandable) and the removal of the RFA needles with or without needle tract
ablation.
3. The same term for hepatocellular carcinoma but not liver cancer should be used in the text.
4. Were there other side effects or complications associated with the use of lusutrombopag? The
authors should describe all of them.
5. In the Discussion section, the researchers should refer to the small number of the enrolled
patients as an evaluation of a certain drug in this study.
assistant